{2-[(4-methyl-1-piperazinyl)methyl]-1-benzothien-5-yl}amine | 478076-74-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: {2-[(4-methyl-1-piperazinyl)methyl]-1-benzothien-5-yl}amine
• 英文别名: 2-(4-Methylpiperazin-1-ylmethyl)benzo[b]thiophen-5-ylamine；2-[(4-Methylpiperazin-1-yl)methyl]-1-benzothiophen-5-amine
• CAS: 478076-74-3
• 化学式: C₁₄H₁₉N₃S
• 分子量: 261.391
• InChiKey: ALSKYUJVXULHBQ-UHFFFAOYSA-N

物化性质

• 沸点：
  430.0±40.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  60.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 5-(4-chlorophenyl)-3-{[(1E)-(dimethylamino)methylidene]amino}-2-thiophenecarboxylate 、 {2-[(4-methyl-1-piperazinyl)methyl]-1-benzothien-5-yl}amine 以 苯酚 为溶剂， 反应 1.5h， 生成 6-(4-chlorophenyl)-3-{2-[(4-methylpiperazin-1-yl)methyl]-1-benzothien-5-yl}thieno[3,2-d]pyrimidin-4(3H)-one
  参考文献：
  名称：

  6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist

  摘要：

  Genetic manipulation studies in mice at both the MCH receptor 1 (MCHR1) as well as the MCH peptide levels have implicated MCHR1 as a key player in energy homeostasis. The phenotype exhibited by these studies, that is, increased metabolic rate, resistance to high fat diet, and subsequent weight loss, has spurred considerable efforts to develop antagonists of MCHR1. In continuation of efforts directed toward this goal, the present work capitalizes on the putative binding mode of an MCH antagonist, resulting in the identification of several novel chemotypes that are potent and selective MCHR1 antagonists. In addition, the favorable pharmacokinetics of representative examples has allowed for the evaluation of an MCHR1 antagonist in a high fat diet-induced obese rodent model of obesity. The tolerability of the right-hand side of the template for diverse chemotypes accompanied by favorable effects on weight loss enhances the attractiveness of this template in the pursuit toward development of effective anti-obesity agents.

  DOI：

  10.1021/jm060814b
• 作为产物：
  描述：

  2-氯-5-硝基苯甲醛 在 Pd/C 氢氧化钾 、 lithium hydroxide 、 lithium aluminium tetrahydride 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、275.79 kPa 条件下， 反应 57.0h， 生成 {2-[(4-methyl-1-piperazinyl)methyl]-1-benzothien-5-yl}amine
  参考文献：
  名称：

  6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist

  摘要：

  Genetic manipulation studies in mice at both the MCH receptor 1 (MCHR1) as well as the MCH peptide levels have implicated MCHR1 as a key player in energy homeostasis. The phenotype exhibited by these studies, that is, increased metabolic rate, resistance to high fat diet, and subsequent weight loss, has spurred considerable efforts to develop antagonists of MCHR1. In continuation of efforts directed toward this goal, the present work capitalizes on the putative binding mode of an MCH antagonist, resulting in the identification of several novel chemotypes that are potent and selective MCHR1 antagonists. In addition, the favorable pharmacokinetics of representative examples has allowed for the evaluation of an MCHR1 antagonist in a high fat diet-induced obese rodent model of obesity. The tolerability of the right-hand side of the template for diverse chemotypes accompanied by favorable effects on weight loss enhances the attractiveness of this template in the pursuit toward development of effective anti-obesity agents.

  DOI：

  10.1021/jm060814b

文献信息

• Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins
  申请人：——

  公开号：US20040204417A1

  公开（公告）日：2004-10-14

  The invention concerns compounds of general formula (1), wherein, in particular; W represents H, SO 2 R 5 . CO(CH 2 ) n R 5 , (CH 2 ) n R 6 , CS(CH 2 ) n R 5 ; X represents S or NH; Y represents (CH 2 ) p , CO, (CH 2 ) p CO, CH═CH—CO; Z represents a hetcrocycle, imidazole, benzimidazole, isoxazole, tetrazole, oxadiazole, thiadazole, pyridine, quinazoline, quinoxaline, quinoline, thiophene; R 1 represents COOR 6 , CONR 6 R 7 , CO—NH—CH(R 6 )—COOR 7 , CH 2 NR 6 R 7 , CH 2 OR 6 , (CH 2 ) p R 6 , CH═CHR 6 ; R 2 represents in particular hydrogen, C 1 -C 10 alkyl, a substituted or unsubstituted phenyl; R 5 and R 6 represents hydrogen, C 1 —C 6 alkyl; R 5 represents a substituted or unsubstituted phenyl or naphthyl; R 6 and R 7 , identical or different, represent hydrogen, C 1 —C 15 alkyl, a hetcrocycle. an aryl; n represents 0 to 10; p represents 1 to 6. 1

  该发明涉及一般式（1）的化合物，其中，特别是；W代表H，SO2R5.CO(CH2)nR5，(CH2)nR6，CS(CH2)nR5；X代表S或NH；Y代表(CH2)p，CO，(CH2)pCO，CH═CH—CO；Z代表杂环，咪唑，苯并咪唑，异噁唑，四唑，噁二唑，硫唑，吡啶，喹唑啉，喹喔啉，喹啉，噻吩；R1代表COOR6，CONR6R7，CO—NH—CH(R6)—COOR7，CH2NR6R7，CH2OR6，(CH2)pR6，CH═CHR6；R2特指氢，C1-C10烷基，取代或未取代苯基；R5和R6代表氢，C1—C6烷基；R5代表取代或未取代苯基或萘基；R6和R7，相同或不同，代表氢，C1—C15烷基，杂环，芳基；n表示0到10；p表示1到6。
• DERIVES DE BENZOTHIENYLE OU D'INDOLE ET LEUR UTILISATION COMME INHIBITEURS DE PROTEINES PRENYL TRANSFERASE
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP1395581A2

  公开（公告）日：2004-03-10
• [EN] NOVEL BENZOTHIENYL OR INDOLE DERIVATIVES, PREPARATION AND USE THEREOF AS INHIBITORS OF PRENYL TRANSFERASE PROTEINS<br/>[FR] NOUVEAUX DERIVES DE BENZOTHIENYLE OU D'INDOLE, LEUR PREPARATION ET LEUR UTILISATION COMME INHIBITEURS DE PROTEINES PRENYL TRANSFERASE
  申请人：PF MEDICAMENT

  公开号：WO2002098852A2

  公开（公告）日：2002-12-12

  L'invention se rapporte à des composés répondant à la formule générale (I): dans laquelle, en particulier, W représente H, SO2R5, CO(CH2)nR5, (ch2)nR6, CS(CH2)nR5; X représente S ou NH; Y représente (CH2)p, CO, (CH2)PCO, CH=CH-CO; Z représente un hétérocycle, imidazole, benzimidazole, isoxazole, tétrazole, oxadiazole, thiadiazole, pyridine, quinazoline, quinoxaline, quinoline, thiophène; R1 représente COOR6, CONR6R7, CO-NH-CH(R6)-COOR7, CH2NR6R7, CH2OR6, (CH2)PR6, CH=CHR6; R2 représente notamment Hydrogène, C1-C10 alkyle un phényle non substitué ou substitué R3 et R4 représente Hydrogène, C1-C6 alkyle; R5 représente un Phényle ou un naphtyle non substitué ou substitue; R6 et R7 identiques ou différents, représentent Hydrogène, C1-C15 alkyle, un hétérocycle, un aryle; n représente 0 à 10 p représente 1 à 6.
• [EN] HETEROCYCLIC MCHR1 ANTAGONISTS<br/>[FR] ANTAGONISTES HETEROCYCLIQUES DE MCHR1
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004092181A9

  公开（公告）日：2005-01-27

  [EN] This invention relates to novel heterocycles which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), also referred to as 11CBy, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines. Compounds of the invention have formula (I).
  [FR] L'invention concerne des dérivés de benzopyrane substitués, des stéréoisomères et des sels pharmaceutiquement acceptables desdits composés, ainsi que des procédés appropriés pour les préparer. Les composés de la présente invention s'utilisent comme agonistes du récepteur beta des oestrogènes. De tels agonistes s'utilisent dans le traitement d'affections induites par le récepteur beta des oestrogènes, telles que le cancer de la prostate ou l'hyperplasie prostatique bénigne (HPB).
• 6-(4-Chlorophenyl)-3-substituted-thieno[3,2-<i>d</i>]pyrimidin-4(3<i>H</i>)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist
  作者：Francis X. Tavares、Kamal A. Al-Barazanji、Michael J. Bishop、Christy S. Britt、David L. Carlton、Joel P. Cooper、Paul L. Feldman、Dulce M. Garrido、Aaron S. Goetz、Mary K. Grizzle、Donald L. Hertzog、Diane M. Ignar、Daniel G. Lang、Maggie S. McIntyre、Ronda J. Ott、Andrew J. Peat、Hui-Qiang Zhou

  DOI：10.1021/jm060814b

  日期：2006.11.30

  Genetic manipulation studies in mice at both the MCH receptor 1 (MCHR1) as well as the MCH peptide levels have implicated MCHR1 as a key player in energy homeostasis. The phenotype exhibited by these studies, that is, increased metabolic rate, resistance to high fat diet, and subsequent weight loss, has spurred considerable efforts to develop antagonists of MCHR1. In continuation of efforts directed toward this goal, the present work capitalizes on the putative binding mode of an MCH antagonist, resulting in the identification of several novel chemotypes that are potent and selective MCHR1 antagonists. In addition, the favorable pharmacokinetics of representative examples has allowed for the evaluation of an MCHR1 antagonist in a high fat diet-induced obese rodent model of obesity. The tolerability of the right-hand side of the template for diverse chemotypes accompanied by favorable effects on weight loss enhances the attractiveness of this template in the pursuit toward development of effective anti-obesity agents.